Quantifying subclinical central nervous lesions in primary antiphospholipid syndrome: The role of magnetization transfer imaging

Journal of Magnetic Resonance Imaging

Volumn 27, Issue 3, 2008, Pages 483-488

  De Andrade, Danieli Castro Oliveira ^a,b   Borba, Eduardo Ferreira ^a   Bonfá, Eloísa ^a   De Carvalho, Jozélio Freire ^a   Da Rocha, Antônio José ^b   Maia Jr , Antônio Carlos ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Fleury   (Brazil)

Author keywords

Antiphospholipid syndrome; Central nervous system; Magnetic resonance imaging; Magnetization transfer imaging

Indexed keywords

ADULT; ANTIPHOSPHOLIPID SYNDROME; APPARATUS; ARTICLE; BRAIN DAMAGE; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FEMALE; HEP 2 CELL; HISTOGRAM; HUMAN; HUMAN CELL; IMAGE ANALYSIS; MALE; MEASUREMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; VOLUMETRY;

ADULT; ANTIBODIES, ANTINUCLEAR; ANTIPHOSPHOLIPID SYNDROME; BRAIN; HUMANS; MAGNETIC RESONANCE IMAGING;

EID: 40449094436     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.21308     Document Type: Article

References (52)

1. Sanna G. Cerebral disease other than stroke and transient ischemic attack in antiphospholipid syndrome. In: Khammashta MA, editor. Hughes syndrome. Antiphospholipid syndrome, 2nd ed. London: Springer; 2006:68-85.
2. Sibbitt WL Jr, Sibbitt RR. Magnetic resonance spectroscopy and positron emission tomography scanning in neuropsychiatric systemic lupus erythematosus. Rheum Dis Clin North Am 1993;19: 851-868.
3. Sibbitt WL Jr, Sibbitt RR, Griffey RH, Eckel C, Bankhurst AD. Magnetic resonance and computed tomographic imaging in the evaluation of acute neuropsychiatric disease in systemic lupus erythematosus. Ann Rheum Dis 1989;48:1014-1022.
4. Steens SC, Admiraal-Behloul F, Bosma GP, et al. Selective gray matter damage in neuropsychiatric lupus. Arthritis Rheum 2004; 50:2877-2881.
5. Gomez-Puerta JA, Cervera R, Calvo LM, et al. Dementia associated with the antiphospholipid syndrome: clinical and radiological characteristics of 30 patients. Rheumatology (Oxford) 2005;44:95-99.
6. Karassa FB, Ioannidis JP, Touloumi G, Boki KA, Moutsopoulos HM. Risk factors for central nervous system involvement in systemic lupus erythematosus. Q J Med 2000;93:169-174.
7. Loevner LA, Grossman RI, Cohen JA, Lexa FJ, Kessler D, Kolson DL. Microscopic disease in normal-appearing white matter on conventional MR images in patients with multiple sclerosis: assessment with magnetization-transfer measurements. Radiology 1995; 196:511-515.
8. Grossman RI, Gomori JM, Ramer KN, Lexa FJ, Schnall MD. Magnetization transfer: theory and clinical applications in neuroradiology. Radiographics 1994;14:279-290.
9. Hiehle JF Jr, Grossman RI, Ramer KN, Gonzalez-Scarano F, Cohen JA. Magnetization transfer effects in MR-detected multiple sclerosis lesions: comparison with gadolinium-enhanced spin-echo images and nonenhanced T1-weighted images. AJNR Am J Neuroradiol 1995;16:69-77.
10. van Buchem MA, Udupa JK, McGowan JC, et al. Global volumetric estimation of disease burden in multiple sclerosis based on magnetization transfer imaging. AJNR Am J Neuroradiol 1997;18: 1287-1290.
11. van Buchem MA, McGowan JC, Kolson DL, Polansky M, Grossman RI. Quantitative volumetric magnetization transfer analysis in multiple sclerosis: estimation of macroscopic and microscopic disease burden. Magn Reson Med 1996;36:632-636.
12. Rovaris M, Viti B, Ciboddo G, et al. Brain involvement in systemic immune mediated diseases: magnetic resonance and magnetisation transfer imaging study. J Neurol Neurosurg Psychiatry 2000; 68:170-177.
13. Bosma GP, Rood MJ, Huizinga TW, de Jong BA, Bollen EL, van Buchem MA. Detection of cerebral involvement in patients with active neuropsychiatric systemic lupus erythematosus by the use of volumetric magnetization transfer imaging. Arthritis Rheum 2000;43:2428-2436.
14. Bosma GP, Rood MJ, Zwinderman AH, Huizinga TW, van Buchem MA. Evidence of central nervous system damage in patients with neuropsychiatric systemic lupus erythematosus, demonstrated by magnetization transfer imaging. Arthritis Rheum 2000;43:48-54.
15. Bosma GP, Steens SC, Petropoulos H, et al. Multisequence magnetic resonance imaging study of neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2004;50:3195-3202.
16. Steens SC, Bosma GP, Steup-Beekman GM, le Cessie S, Huizinga TW, van Buchem MA. Association between microscopic brain damage as indicated by magnetization transfer imaging and anticardiolipin antibodies in neuropsychiatric lupus. Arthritis Res Ther 2006; 8:R38.-
17. Lockshin MD, Sammaritano LR, Schwartzman S. Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum 2000;43:440-443.
18. Newman WP, 3rd, Freedman DS, Voors AW, et al. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study. N Engl J Med 1986;314:138-144.
19. Gharavi AE, Harris EN, Asherson RA, Hughes GR. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis 1987;46:1-6.
20. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995;74:1185-1190.
21. Tofts P, Steens S, Cercignani M, et al. Sources of variation in multi-centre brain MTR histogram studies: body-coil transmission eliminates inter-centre differences. Magn Reson Mater Phys Biol Med 2006;19:209-222.
22. Dehmeshki J, Barker GJ, Tofts PS. Classification of disease subgroup and correlation with disease severity using magnetic resonance imaging whole-brain histograms: application to magnetization transfer ratios and multiple sclerosis. IEEE Trans Med Imaging 2002;21:320-331.
23. Schmidt R, Enzinger C, Ropele S, Schmidt H, Fazekas F. Progression of cerebral white matter lesions: 6-year results of the Austrian Stroke Prevention Study. Lancet 2003;361:2046-2048.
24. Schmidt R, Schmidt H, Fazekas F, et al. MRI cerebral white matter lesions and paraoxonase PON1 polymorphisms: three-year follow-up of the austrian stroke prevention study. Arterioscler Thromb Vasc Biol 2000;20:1811-1816.
25. Dehmeshki J, Ruto AC, Arridge S, Silver NC, Miller DH, Tofts PS. Analysis of MTR histograms in multiple sclerosis using principal components and multiple discriminant analysis. Magn Reson Med 2001;46:600-609.
26. Dehmeshki J, Van Buchem MA, Bosma GP, Huizinga TW, Tofts PS. Systemic lupus erythematosus: diagnostic application of magnetization transfer ratio histograms in patients with neuropsychiatric symptoms - initial results. Radiology 2002;222:722-728.
27. Erickson BJ, Noseworthy JH. Value of magnetic resonance imaging in assessing efficacy in clinical trials of multiple sclerosis therapies. Mayo Clin Proc 1997;72:1080-1089.
28. Petrella JR, Grossman RI, McGowan JC, Campbell G, Cohen JA. Multiple sclerosis lesions: relationship between MR enhancement pattern and magnetization transfer effect. AJNR Am J Neuroradiol 1996;17:1041-1049.
29. Mehta RC, Pike GB, Enzmann DR. Measure of magnetization transfer in multiple sclerosis demyelinating plaques, white matter ischemic lesions, and edema. AJNR Am J Neuroradiol 1996;17:1051-1055.
30. Loevner LA, Grossman RI, McGowan JC, Ramer KN, Cohen JA. Characterization of multiple sclerosis plaques with T1-weighted MR and quantitative magnetization transfer. AJNR Am J Neuroradiol 1995;16:1473-1479.
31. van der Flier WM, van den Heuvel DM, Weverling-Rijnsburger AW, et al. Magnetization transfer imaging in normal aging, mild cognitive impairment, and Alzheimer's disease. Ann Neurol 2002;52:62-67.
32. Filippi M, Falini A, Arnold DL, et al. Magnetic resonance techniques for the in vivo assessment of multiple sclerosis pathology: consensus report of the white matter study group. J Magn Reson Imaging 2005;21:669-675.
33. Filippi M, Dousset V, McFarland HF, Miller DH, Grossman RI. Role of magnetic resonance imaging in the diagnosis and monitoring of multiple sclerosis: consensus report of the White Matter Study Group. J Magn Reson Imaging 2002;15:499-504.
34. Campi A, Filippi M, Comi G, Scotti G, Gerevini S, Dousset V. Magnetisation transfer ratios of contrast-enhancing and non-enhancing lesions in multiple sclerosis. Neuroradiology 1996;38: 115-119.
35. Miller DH, Grossman RI, Reingold SC, McFarland HF. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998;121(Pt 1):3-24.
36. van Waesberghe JH, van Walderveen MA, Castelijns JA, et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. AJNR Am J Neuroradiol 1998;19:675-683.
37. Huizinga TW, Steens SC, van Buchem MA. Imaging modalities in central nervous system systemic lupus erythematosus. Curr Opin Rheumatol 2001;13:383-388.
38. Bluestein HG, Zvaifler NJ. Antibodies reactive with central nervous system antigens. Hum Pathol 1983;14:424-428.
39. Denburg JA, Carbotte RM, Denburg SD. Neuronal antibodies and cognitive function in systemic lupus erythematosus. Neurology 1987;37:464-467.
40. Kelly MC, Denburg JA. Cerebrospinal fluid immunoglobulins and neuronal antibodies in neuropsychiatric systemic lupus erythematosus and related conditions. J Rheumatol 1987;14:740-744.
41. Avinoach I, Amital-Teplizki H, Kuperman O, Isenberg DA, Shoenfeld Y. Characteristics of antineuronal antibodies in systemic lupus erythematosus patients with and without central nervous system involvement: the role of mycobacterial cross-reacting antigens. Isr J Med Sci 1990;26:367-373.
42. Rubbert A, Marienhagen J, Pirner K, et al. Single-photon-emission computed tomography analysis of cerebral blood flow in the evaluation of central nervous system involvement in patients with systemic lupus erythematosus. Arthritis Rheum 1993;36:1253-1262.
43. Russo R, Gilday D, Laxer RM, Eddy A, Silverman ED. Single photon emission computed tomography scanning in childhood systemic lupus erythematosus. J Rheumatol 1998;25:576-582.
44. Zvaifler NJ, Bluestein HG. The pathogenesis of central nervous system manifestations of systemic lupus erythematosus. Arthritis Rheum 1982;25:862-866.
45. Bosma GP, Middelkoop HA, Rood MJ, Bollen EL, Huizinga TW, van Buchem MA. Association of global brain damage and clinical functioning in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2002;46:2665-2672.
46. Emmer BJ, Steens SC, Steup-Beekman GM, et al. Detection of change in CNS involvement in neuropsychiatric SLE: a magnetization transfer study. J Magn Reson Imaging 2006;24:812-816.
47. Del Papa N, Guidali L, Sala A, et al. Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arthritis Rheum 1997;40:551-561.
48. Oosting JD, Derksen RH, Blokzijl L, Sixma JJ, de Groot PG. Antiphospholipid antibody positive sera enhance endothelial cell procoagulant activity - studies in a thrombosis model. Thromb Haemost 1992;68:278-284.
49. Simantov R, LaSala JM, Lo SK, et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995;96:2211-2219.
50. Meroni PL, Tincani A, Sepp N, et al. Endothelium and the brain in CNS lupus. Lupus 2003;12:919-928.
51. Sun KH, Liu WT, Tsai CY, Liao TS, Lin WM, Yu CL. Inhibition of astrocyte proliferation and binding to brain tissue of anticardiolipin antibodies purified from lupus serum. Ann Rheum Dis 1992;51: 707-712.
52. Khalili A, Cooper RC. A study of immune responses to myelin and cardiolipin in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1991;85:365-372.